Q2 EPS Forecast for Dianthus Therapeutics Raised by Analyst

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Equities research analysts at HC Wainwright increased their Q2 2026 earnings estimates for Dianthus Therapeutics in a research report issued on Wednesday, May 6th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($1.23) per share for the quarter, up from their prior forecast of ($1.55). HC Wainwright currently has a “Buy” rating and a $130.00 target price on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($4.46) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q3 2026 earnings at ($1.43) EPS, Q4 2026 earnings at ($1.48) EPS, FY2026 earnings at ($4.81) EPS, Q1 2027 earnings at ($1.50) EPS, Q2 2027 earnings at ($1.40) EPS, Q3 2027 earnings at ($1.40) EPS, Q4 2027 earnings at ($1.41) EPS and FY2027 earnings at ($5.49) EPS.

Other equities research analysts have also issued research reports about the stock. Wedbush boosted their price target on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a report on Monday, March 9th. Raymond James Financial upgraded shares of Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price target for the company from $63.00 to $123.00 in a report on Tuesday, March 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Monday, April 20th. Finally, Oppenheimer boosted their price objective on shares of Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Dianthus Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $117.82.

Dianthus Therapeutics Price Performance

DNTH stock opened at $85.47 on Friday. Dianthus Therapeutics has a 52-week low of $16.64 and a 52-week high of $96.50. The company’s 50 day simple moving average is $81.01 and its 200-day simple moving average is $56.30. The firm has a market capitalization of $4.67 billion, a P/E ratio of -20.69 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.25. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 38.79%. The business had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million.

Institutional Trading of Dianthus Therapeutics

Large investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. bought a new stake in Dianthus Therapeutics in the second quarter worth approximately $27,000. First Horizon Corp bought a new stake in Dianthus Therapeutics in the first quarter worth approximately $32,000. Parkside Financial Bank & Trust grew its position in Dianthus Therapeutics by 131.7% in the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after acquiring an additional 540 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Dianthus Therapeutics in the fourth quarter worth approximately $40,000. Finally, Russell Investments Group Ltd. bought a new stake in Dianthus Therapeutics in the third quarter worth approximately $64,000. 47.53% of the stock is owned by institutional investors.

Insider Activity at Dianthus Therapeutics

In related news, CAO Edward Carr sold 43,682 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $3,559,646.18. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Marino Garcia sold 122,918 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $10,016,587.82. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 323,021 shares of company stock valued at $26,564,008. Company insiders own 3.02% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.